NUCLEOSIDE ANALOGUES, STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION
Author(s)
Tsan Y1, Lin M2, Ho W2, Chen P3
1Taichung Veterans General Hospital, Taichung, Taiwan, 2Department of Public Health, China Medical University, Taichung, Taiwan, 3Department of Public Health, National Taiwan University College of Public Health, Taipei, Taiwan
OBJECTIVES: Statins may have protective effects against hepatocellular cancer, but no studies have focused on their clinical interactions with nucleoside analogues(NAs) in patients with chronic hepatitis B virus (HBV) infection. The purpose of this study was to investigate the association between the use of NAs, statins and the risk of hepatocellular carcinoma (HCC) in HBV-infected patients. METHODS: A population-based matched cohort study of 91,265 HBV-infected patients enrolled in the Taiwan National Health Insurance Research Database since October, 2003 and December, 2010. 18,253 patients with NAs use were 1:4 matched as 73,012 patients without NAs use according to index date, age, sex, diabetes, liver cirrhosis, hypertension, hyperlipidemia, biliary tract stones, chronic renal injury, alcohol related diseases, and COPD. Cox proportional hazards regression model for drug exposures was employed to evaluate the association between NAs, statin use and HCC risk. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN24
Topic
Epidemiology & Public Health
Disease
Gastrointestinal Disorders, Oncology